(MENAFN- GlobeNewsWire - Nasdaq) The anticancer drug market presents opportunities driven by rising global cancer incidence, an aging population, and advancements in AI for drug discovery. Investing in novel therapies and AI integration can streamline development, addressing growing demand and optimizing costs, particularly targeting advanced therapies in emerging regions.Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Anticancer Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets's offering.
The Global Anticancer Drug Market, valued at USD 179.93 Billion in 2024, is projected to experience a CAGR of 5.25% to reach USD 244.59 Billion by 2030
Anticancer drugs represent pharmaceutical agents specifically formulated to inhibit or destroy malignant cells, serving as the cornerstone for various cancer treatment strategies. The market's expansion is primarily driven by the escalating global incidence of cancer, an expanding aging population predisposed to oncological diseases, and continuous advancements in medical research that foster novel therapeutic breakthroughs.
![]()
The increasing global cancer incidence substantially propels the anticancer drug market. A growing patient population naturally leads to a higher demand for diagnostic tools and subsequent therapeutic interventions, from chemotherapy to advanced targeted therapies. This demographic shift intensifies the need for a continuous supply of effective pharmaceuticals, driving companies to expand their portfolios. According to the International Agency for Research on Cancer, in 2022, there were an estimated 20 million new cancer cases worldwide, indicating a vast and expanding patient pool requiring treatment. The persistent rise in various cancer types underscores the demand for innovative drug solutions.
Key Market Challenges
A significant challenge impeding the growth of the global anticancer drug market is the considerable cost associated with the development and provision of advanced therapies. These high costs directly restrict patient access and affordability, particularly within emerging economies. This limitation reduces the eligible patient population for novel treatments, thereby hampering market penetration and overall sales volumes globally.
Key Market Trends
The integration of artificial intelligence (AI) in oncology is profoundly reshaping drug discovery and development processes. AI algorithms can analyze vast datasets, identify novel drug targets, and predict compound efficacy with increased speed and accuracy compared to traditional methods. This technological advancement significantly reduces the time and cost associated with bringing new anticancer drugs to market, fostering a more efficient and productive pipeline.
According to Silicon Valley Bank, biotech AI attracted $5.6 billion in 2024, constituting nearly 30% of healthcare startup funding, reflecting a substantial increase driven by significant investment deals. This influx of capital underscores the industry's confidence in AI's transformative potential. For example, Insilico Medicine announced in June 2023 that its small molecule inhibitor drug candidate, INS018_055, an entirely AI-discovered and AI-designed drug, entered a phase 2 clinical trial for idiopathic pulmonary fibrosis, demonstrating the tangible progress of AI in therapeutic advancement.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 185 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value (USD) in 2024 | $179.93 Billion |
| Forecasted Market Value (USD) by 2030 | $244.59 Billion |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
Report Scope:
Key Market Players Profiled:
F. Hoffmann-La Roche Ltd. Genentech, Inc. Novartis AG Pfizer Inc. Bristol-Myers Squibb Company GlaxoSmithKline plc. Eli Lilly and Company (India) Pvt. Ltd. AstraZeneca plc Sanofi S.A. Bayer AG
By Indication:
Breast Cancer Blood Cancer Prostate Cancer Gastrointestinal Cancer Gynecologic Cancer Lung Cancer Others
By Drug:
Cytotoxics Hormonal Therapy Targeted Therapy Others
By Route of Administration:
By End User:
Hospitals & Clinics Ambulatory Care Centers Others
By Region:
North America Europe Asia-Pacific South America Middle East & Africa
For more information about this report visit
About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
CONTACT:
CONTACT:
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
![]()
MENAFN02122025004107003653ID1110425593
Comments
No comment